Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Japanese (NIKKEI) Pharma Industry Analysis

UpdatedAug 07, 2026
DataAggregated Company Financials
Companies39
  • 7D-3.1%
  • 3M-3.0%
  • 1Y7.8%
  • YTD-5.4%

Over the last 7 days, the Pharma industry has dropped 6.5%, driven by pullbacks in Chugai Pharmaceutical and Takeda Pharmaceutical of 4.3% and 5.1%, respectively. Meanwhile, Otsuka Holdings actually outperformed within the industry, gaining 7.7% in the last week. This takes the industry's 12 month performance to a gain of 5.0%. Earnings are forecast to grow by 13% annually.

Industry Valuation and Performance

Has the Japanese Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 07 Aug 2026JP¥44.4tJP¥18.1tJP¥2.0t15.8x21.7x2.5x
Sun, 05 Jul 2026JP¥45.2tJP¥17.5tJP¥1.9t16.7x24.2x2.6x
Tue, 02 Jun 2026JP¥45.8tJP¥17.5tJP¥2.2t16.5x20.7x2.6x
Thu, 30 Apr 2026JP¥46.7tJP¥17.4tJP¥2.2t15.7x21.4x2.7x
Sat, 28 Mar 2026JP¥50.5tJP¥17.3tJP¥2.2t16.6x23.2x2.9x
Mon, 23 Feb 2026JP¥52.5tJP¥17.3tJP¥2.2t15.9x24.1x3x
Wed, 21 Jan 2026JP¥46.6tJP¥16.9tJP¥1.9t16.5x24.4x2.8x
Fri, 19 Dec 2025JP¥45.5tJP¥16.9tJP¥1.9t16.5x23.9x2.7x
Sun, 16 Nov 2025JP¥44.3tJP¥16.9tJP¥1.9t15.3x23.1x2.6x
Tue, 14 Oct 2025JP¥42.5tJP¥16.8tJP¥1.8t15.4x23.3x2.5x
Thu, 11 Sep 2025JP¥41.4tJP¥16.8tJP¥1.8t16.3x22.7x2.5x
Sat, 09 Aug 2025JP¥39.4tJP¥16.8tJP¥1.8t15.7x21.6x2.3x
Mon, 07 Jul 2025JP¥39.4tJP¥16.8tJP¥1.8t15x22.4x2.3x
Wed, 04 Jun 2025JP¥40.6tJP¥16.8tJP¥1.8t14.6x23x2.4x
Fri, 02 May 2025JP¥42.2tJP¥16.7tJP¥1.7t14.9x24.9x2.5x
Sun, 30 Mar 2025JP¥40.7tJP¥16.5tJP¥1.5t15.7x27.1x2.5x
Tue, 25 Feb 2025JP¥40.4tJP¥16.5tJP¥1.5t15.8x26.9x2.5x
Thu, 23 Jan 2025JP¥41.0tJP¥16.1tJP¥1.4t15.4x29.1x2.6x
Sat, 21 Dec 2024JP¥41.4tJP¥16.1tJP¥1.4t15.3x29.3x2.6x
Mon, 18 Nov 2024JP¥43.9tJP¥16.1tJP¥1.4t15.1x31.1x2.7x
Wed, 16 Oct 2024JP¥45.4tJP¥15.6tJP¥1.2t15.8x37.8x2.9x
Fri, 13 Sep 2024JP¥44.7tJP¥15.5tJP¥1.2t17.7x37.2x2.9x
Sun, 11 Aug 2024JP¥43.2tJP¥15.5tJP¥1.2t16.3x35.9x2.8x
Tue, 09 Jul 2024JP¥44.0tJP¥15.0tJP¥1.1t18.6x40.2x2.9x
Thu, 06 Jun 2024JP¥41.3tJP¥15.0tJP¥1.1t18.1x37.7x2.7x
Sat, 04 May 2024JP¥41.3tJP¥14.9tJP¥1.3t18.8x33x2.8x
Mon, 01 Apr 2024JP¥42.2tJP¥15.1tJP¥1.2t20.1x34.7x2.8x
Wed, 28 Feb 2024JP¥43.6tJP¥15.1tJP¥1.2t20.7x35.8x2.9x
Fri, 26 Jan 2024JP¥40.7tJP¥15.2tJP¥1.4t19.7x29.6x2.7x
Sun, 24 Dec 2023JP¥38.4tJP¥15.2tJP¥1.4t19.4x28x2.5x
Tue, 21 Nov 2023JP¥38.9tJP¥15.2tJP¥1.4t19.7x28.3x2.6x
Thu, 19 Oct 2023JP¥39.4tJP¥14.9tJP¥1.4t23.6x27.6x2.6x
Sat, 16 Sep 2023JP¥41.0tJP¥14.9tJP¥1.4t24.6x28.7x2.7x
Mon, 14 Aug 2023JP¥40.5tJP¥14.9tJP¥1.4t22.9x28.4x2.7x
Price to Earnings Ratio

28.4x


Total Market Cap: JP¥40.5tTotal Earnings: JP¥1.4tTotal Revenue: JP¥14.9tTotal Market Cap vs Earnings and Revenue0%0%0%
Japanese Pharma Industry Price to Earnings3Y Average 28.1x202420252026
Current Industry PE
  • Investors are pessimistic on the Japanese Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 22.0x which is lower than its 3-year average PE of 28.1x.
  • The industry is trading close to its 3-year average PS ratio of 2.7x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 11% per year over the last three years.
  • Revenues for these companies have grown 6.4% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Japanese Healthcare industry?

JP Market2.77%
Healthcare-1.65%
Pharma-3.11%
Pharma-3.11%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
4578 Otsuka HoldingsJP¥12.17k7.7%
+JP¥455.3b		59.3%PE15.8x
4503 Astellas PharmaJP¥2.29k0.07%
+JP¥6.2b		42.6%PE11.2x
4516 Nippon ShinyakuJP¥3.54k1.3%
+JP¥3.0b		8.7%PE8x
4889 RenascienceJP¥1.54k11.0%
+JP¥2.1b		-49.9%PS311.4x
4565 Nxera PharmaJP¥869.001.8%
+JP¥1.4b		-2.4%PS2.4x

Latest News

4502
JP¥5,425.00
Takeda Pharmaceutical
7D
-5.1%
1Y
28.3%
4507
JP¥2,825.50
Shionogi
7D
-7.1%
1Y
7.7%
Analysis Article • Aug 05

Shionogi & Co., Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Shionogi & Co., Ltd. ( TSE:4507 ) just released its first-quarter report and things are looking bullish. The company...
4523
JP¥4,691.00
Eisai
7D
-6.8%
1Y
8.1%
Analysis Article • Aug 05

Results: Eisai Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

As you might know, Eisai Co., Ltd. ( TSE:4523 ) just kicked off its latest quarterly results with some very strong...
4503
JP¥2,288.50
Astellas Pharma
7D
0.07%
1Y
42.6%
Narrative Update • Aug 05

4503: Oncology Approvals And Trial Updates Will Drive Future Upside Potential

Analysts have raised their price target for Astellas Pharma from ¥2,950 to about ¥3,098, reflecting updated assumptions around slightly less revenue decline, a modestly lower profit margin, and a higher future P/E multiple. What's in the News Astellas Pharma and Pfizer received U.S. FDA approval for PADCEV plus Keytruda or Keytruda QLEX as neoadjuvant and adjuvant treatment for adult patients with muscle invasive bladder cancer, regardless of cisplatin eligibility, based on Phase 3 EV-304 data presented at the 2026 ASCO Genitourinary Cancers Symposium.
4578
JP¥12,170.00
Otsuka Holdings
7D
7.7%
1Y
59.3%
Narrative Update • Aug 05

4578: Rising Dividends And Completed Buyback Will Support A Stronger Bullish Case

The analyst price target for Otsuka Holdings has been updated from ¥13,025 to about ¥13,392, with analysts pointing to revised assumptions that combine a lower revenue growth outlook, a slightly higher projected profit margin, and a modestly adjusted future P/E multiple. What's in the News for Otsuka Holdings Otsuka Holdings has a board meeting scheduled for July 31, 2026 to review and approve a revised consolidated financial forecast for the fiscal year ending December 31, 2026, along with other agenda items.
8095
JP¥520.00
Astena Holdings
7D
3.4%
1Y
1.4%
4151
JP¥2,514.00
Kyowa Kirin
7D
-5.1%
1Y
-6.4%
4528
JP¥2,338.00
Ono Pharmaceutical
7D
-4.9%
1Y
37.4%
4568
JP¥2,660.00
Daiichi Sankyo Company
7D
-7.9%
1Y
-26.1%
4516
JP¥3,539.00
Nippon Shinyaku
7D
1.3%
1Y
8.7%
4519
JP¥6,764.00
Chugai Pharmaceutical
7D
-4.3%
1Y
-8.6%
Narrative Update • Jul 31

4519: Higher 2026 Earnings Guidance And Dividend Outlook Will Support Bullish View

Analysts have trimmed their price target for Chugai Pharmaceutical to about ¥9,687 from roughly ¥9,973, reflecting slightly lower revenue growth assumptions and a more moderate future P/E multiple while keeping expected profit margins broadly similar. What's in the News Chugai Pharmaceutical issued consolidated earnings guidance for the fiscal year ending December 31, 2026, with expected revenue of ¥1,345,000 million, Core operating profit of ¥670,000 million, Core net income of ¥485,000 million, and Core earnings per share of ¥295.00.
4536
JP¥1,876.00
Santen Pharmaceutical
7D
-3.1%
1Y
12.7%
4596
JP¥63.00
Kubota Pharmaceutical Holdings
7D
8.6%
1Y
28.6%
4565
JP¥869.00
Nxera Pharma
7D
1.8%
1Y
-2.4%
4579
JP¥509.00
RaQualia Pharma
7D
9.5%
1Y
-4.1%
4889
JP¥1,537.00
Renascience
7D
11.0%
1Y
-49.9%